Evidence map›Paper›PMID 40069095›Full record

ArticleThe American journal on addictions2025

Elevated rate of suicide risk in individuals with opioid use disorder.

Max Spaderna, Elana Rosenthal, Sun Jung Kang, Rahwa Eyasu, Emade Ebah, Onyinyechi Ogbumbadiugha, Phyllis Bijole, Amelia Cover, Ashley Davis, Meredith Zoltick and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal on addictions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Max SpadernaDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID http://orcid.org/0000-0002-0877-5113
Elana RosenthalDivision of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Sun Jung KangGenetic Epidemiology Research Branch, Intramural Research Program, National Institute of Mental Health, Bethesda, Maryland, USA.
Rahwa EyasuDivision of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Emade EbahDivision of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Onyinyechi OgbumbadiughaDivision of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Phyllis BijoleWashington, District of Columbia, USA.
Amelia CoverDivision of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Ashley DavisDivision of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Meredith ZoltickDivision of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Sita KottililDivision of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Julia MountDC Partnership for HIV/AIDS Progress, Clinical Research Program, Washington, District of Columbia, USA.
Catherine GannonDC Partnership for HIV/AIDS Progress, Clinical Research Program, Washington, District of Columbia, USA.
Jasmine StevensDC Partnership for HIV/AIDS Progress, Clinical Research Program, Washington, District of Columbia, USA.
Grace GarrettDivision of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Meghan DerenoncourtDivision of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Tina LiuDC Partnership for HIV/AIDS Progress, Clinical Research Program, Washington, District of Columbia, USA.
Lisa HorowitzOffice of the Clinical Director, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
Maryland PaoOffice of the Clinical Director, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
Sarah KattakuzhyDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Funding

Psychiatry Consultation Liaison Service ResearchZIAMH002922 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI PAO, MARYLAND · 2009 to 2025
$11.5M
Intramural NIH HHS ZIA MH002922Intramural Research Program of the National Institute of Mental Health ZIAMH002922-16
6 · The paper itself

Abstract

BACKGROUND AND

objectivesFew studies have longitudinally investigated suicide risk (SR) in opioid use disorder (OUD). This investigation administered three screening tools to individuals with OUD to compare rates of and variables associated with SR over 12 months.

methods121 individuals meeting criteria for OUD within the past 3 years were administered Item #9 of Patient Health Questionnaire-9 (PHQ-Item-9), the twelfth item of DSM-5-TR Self-Rated Level 1 Cross-Cutting Measure (CCSM-Item-12), and the Ask Suicide-Screening Questions (ASQ) to detect SR at Day 0 and Months 6 and 12. A partitioned generalized methods of moment (GMM) model identified variables associated with SR.

resultsAt Day 0, screen-positive rates for SR were 30% for ASQ, 12.4% for PHQ-Item-9, and 4.1% for CCSM-Item-12. Rates were similar at Months 6 and 12. Variables significantly associated with SR by PHQ-Item-9 were intentional overdose history (p < .001), poor sleep (p < .001), meeting criteria for psychosis (p < .001), and meeting criteria for mania (p = .005). Variables significantly associated with SR by ASQ were intentional overdose history (p < .001), female gender (p = .003), meeting criteria for psychosis (p = .001), and total PHQ-9 score (p = .032). Too few participants endorsed SR by CCSM-Item-12 to be included. DISCUSSION AND

conclusionsIn the OUD population, screening positive for SR was unchanged over 1 year, but detection rates varied by screening tool. History of intentional opioid overdose is independently associated with screening positive for SR. SCIENTIFIC SIGNIFICANCE: This is the first study to evaluate SR in the OUD population using more than one screening tool, and to show an association of history of intentional opioid overdose with SR.

Indexed as

Opioid-Related DisordersSuicideAdultFemaleHumansLongitudinal StudiesMaleMiddle AgedRisk FactorsYoung Adult

Identifiers

PMID40069095
PMCPMC12182714

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.